Santiago Rivera

List of Publications by Year
in descending order

31 papers	1,781 citations	304743 22 h-index	434195 31 g-index
32 all docs	32 docs citations	32 times ranked	2633 citing authors

#	Article	IF	Citations
1	Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?. Journal of Neuroscience, 2010, 30, 15337-15357.	3.6	204
2	Neuronal activityâ€dependent increase of net matrix metalloproteinase activity is associated with MMPâ€9 neurotoxicity after kainate. European Journal of Neuroscience, 2003, 18, 1507-1517.	2.6	161
3	Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 33.	10.8	138
4	Cerebrovascular pathology during the progression of experimental Alzheimer's disease. Neurobiology of Disease, 2016, 88, 107-117.	4.4	107
5	Differential vesicular distribution and trafficking of MMPâ€2, MMPâ€9, and their inhibitors in astrocytes. Glia, 2010, 58, 344-366.	4.9	105
6	MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2016, 73, 217-236.	5.4	96
7	Onset of hippocampusâ€dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease. Hippocampus, 2014, 24, 762-772.	1.9	89
8	Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Molecular and Cellular Neurosciences, 2008, 39, 549-568.	2.2	84
9	Evidence for Early Cognitive Impairment Related to Frontal Cortex in the 5XFAD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 781-796.	2.6	79
10	Area-Specific Alterations of Synaptic Plasticity in the 5XFAD Mouse Model of Alzheimerâ€™s Disease: Dissociation between Somatosensory Cortex and Hippocampus. PLoS ONE, 2013, 8, e74667.	2.5	78
11	Metalloproteinases and their tissue inhibitors in Alzheimerâ€™s disease and other neurodegenerative disorders. Cellular and Molecular Life Sciences, 2019, 76, 3167-3191.	5.4	73
12	Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of AlzheimerÃ¢â‚¬â„¢s disease: evidence for a pro-amyloidogenic role of MT1-MMP. Frontiers in Aging Neuroscience, 2014, 6, 247.	3.4	60
13	A New Role for TIMP-1 in Modulating Neurite Outgrowth and Morphology of Cortical Neurons. PLoS ONE, 2009, 4, e8289.	2.5	49
14	Emerging Alternative Proteinases in APP Metabolism and Alzheimerâ€™s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP. Frontiers in Aging Neuroscience, 2019, 11, 244.	3.4	46
15	Matrix Metalloproteinases as New Targets in Alzheimerâ€™s Disease: Opportunities and Challenges. Journal of Medicinal Chemistry, 2020, 63, 10705-10725.	6.4	42
16	Role of Matrix Metalloproteinases in Migration and Neurotrophic Properties of Nasal Olfactory Stem and Ensheathing Cells. Cell Transplantation, 2013, 22, 993-1010.	2.5	41
17	Chronic treatments with a 5-HT 4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. Neuropharmacology, 2017, 126, 128-141.	4.1	41
18	Trafficking and secretion of matrix metalloproteinaseâ€2 in olfactory ensheathing glial cells: A role in cell migration?. Glia, 2011, 59, 750-770.	4.9	40

#	Article	IF	Citations
19	Endogenous and synthetic MMP inhibitors in CNS physiopathology. Progress in Brain Research, 2014, 214, 313-351.	1.4	39
20	Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimerâ€™s disease: Alleviation by pantethine. PLoS ONE, 2017, 12, e0175369.	2.5	37
21	MT5-MMP Promotes Alzheimerâ€™s Pathogenesis in the Frontal Cortex of 5xFAD Mice and APP Trafficking in vitro. Frontiers in Molecular Neuroscience, 2016, 9, 163.	2.9	34
22	MT5-MMP, just a new APP processing proteinase in Alzheimerâ€™s disease?. Journal of Neuroinflammation, 2016, 13, 167.	7.2	26
23	Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMPâ€2 and BACEâ€1 activities, and the modulation of APP trafficking. FASEB Journal, 2019, 33, 2910-2927.	0.5	25
24	Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study. BMC Neuroscience, 2005, 6, 68.	1.9	24
25	Donecopride, a Swiss army knife with potential against Alzheimer's disease. British Journal of Pharmacology, 2020, 177, 1988-2005.	5.4	19
26	Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model. Neurotherapeutics, 2019, 16, 1237-1254.	4.4	9
27	Metalloproteinases in nervous system function and pathology: introduction. Cellular and Molecular Life Sciences, 2019, 76, 3051-3053.	5.4	9
28	Neurogenesis in gerbil hippocampus following brain ischemia: focus on the involvement of metalloproteinases. Acta Neurobiologiae Experimentalis, 2009, 69, 52-61.	0.7	9
29	MT5-MMP promotes neuroinflammation, neuronal excitability and AÎ² production in primary neuron/astrocyte cultures from the 5xFAD mouse model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, 65.	7.2	9
30	MT5â€MMP controls APP and Î²â€CTF/C99 metabolism through proteolyticâ€dependent and â€independent mechanisms relevant for Alzheimer's disease. FASEB Journal, 2021, 35, e21727.	0.5	6
31	Deficiency in MT5-MMP Supports Branching of Human iPSCs-Derived Neurons and Reduces Expression of GLAST/S100 in iPSCs-Derived Astrocytes. Cells, 2021, 10, 1705.	4.1	2